{"id":"receptor-agonists-glp1ra","safety":{"commonSideEffects":[{"rate":"20–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"10–20","effect":"Constipation"},{"rate":"5–15","effect":"Abdominal pain"},{"rate":"5–10","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GLP-1 receptor agonists bind to and activate GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion. They simultaneously inhibit glucagon release from alpha cells and delay gastric emptying, reducing postprandial glucose excursions. These agents also promote satiety and may have cardiovascular and weight loss benefits.","oneSentence":"GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:01.694Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06500143","phase":"","title":"Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery","status":"COMPLETED","sponsor":"Ciusss de L'Est de l'Île de Montréal","startDate":"2024-10-09","conditions":"Gastric Retention","enrollment":94},{"nctId":"NCT07309094","phase":"","title":"Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD","status":"RECRUITING","sponsor":"Cardenal Herrera University","startDate":"2023-09-15","conditions":"Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 1","enrollment":250},{"nctId":"NCT07276763","phase":"","title":"Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-12-10","conditions":"Gastric Retention","enrollment":16509},{"nctId":"NCT07244003","phase":"PHASE4","title":"Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-03-29","conditions":"T2DM (Type 2 Diabetes Mellitus)","enrollment":430},{"nctId":"NCT05073692","phase":"","title":"Comparison of Type 2 Diabetes Pharmacotherapy Regimens","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2021-07-01","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Diseases","enrollment":241981},{"nctId":"NCT06889454","phase":"","title":"Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS","status":"RECRUITING","sponsor":"Attikon Hospital","startDate":"2024-02-01","conditions":"PCOS, Hyperinsulinism, Hyperandrogenism","enrollment":120},{"nctId":"NCT07115069","phase":"","title":"Comparison of Body Composition Changes With Weight Loss Interventions","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2025-08-09","conditions":"Obesity","enrollment":60},{"nctId":"NCT06256419","phase":"NA","title":"Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM","status":"RECRUITING","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2024-01-01","conditions":"Type 2 Diabetes Mellitus, Susceptibility, Genetic","enrollment":300},{"nctId":"NCT06807970","phase":"EARLY_PHASE1","title":"Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor Agonist","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-09-01","conditions":"Osteoarthritis (OA) of the Knee","enrollment":54},{"nctId":"NCT07017270","phase":"PHASE4","title":"Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","status":"NOT_YET_RECRUITING","sponsor":"Unity Health Toronto","startDate":"2025-07","conditions":"Kidney Disease, Chronic, Diabetes, Dialysis","enrollment":100},{"nctId":"NCT06582875","phase":"PHASE2","title":"Glucagon-Like Peptide-1 Receptor Agonist in ADPKD","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2025-03-06","conditions":"Autosomal Dominant Polycystic Kidney, Obesity","enrollment":126},{"nctId":"NCT06825182","phase":"PHASE3","title":"Current Status of Islet Alpha Cell Function in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-11-07","conditions":"Type 2 Diabetes Mellitus","enrollment":1000},{"nctId":"NCT06449235","phase":"PHASE4","title":"Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh","status":"NOT_YET_RECRUITING","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2024-09","conditions":"Type2diabetes","enrollment":938},{"nctId":"NCT06344247","phase":"NA","title":"Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-09-01","conditions":"Obesity, Chronic Kidney Diseases","enrollment":48},{"nctId":"NCT05578352","phase":"NA","title":"The Exploreration of the Management for the Positive IAA in Patients With Type 2 Diabetes After Premix Insulin Therapy","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-08-05","conditions":"Type 2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT05535322","phase":"","title":"Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity","status":"COMPLETED","sponsor":"Ana Palanca","startDate":"2014-01-01","conditions":"Type 2 Diabetes, Obesity","enrollment":26944},{"nctId":"NCT04184947","phase":"","title":"Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists","status":"COMPLETED","sponsor":"University of Padova","startDate":"2014-03-01","conditions":"Type 2 Diabetes","enrollment":10000},{"nctId":"NCT03959865","phase":"","title":"GLP-1 REceptor Agonists and Real World EvIdeNce","status":"UNKNOWN","sponsor":"University of Padova","startDate":"2018-12-19","conditions":"Type 2 Diabetes","enrollment":6000},{"nctId":"NCT01744236","phase":"PHASE4","title":"SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Receptor Agonists (GLP1RA)","genericName":"Receptor Agonists (GLP1RA)","companyName":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","companyId":"bangladesh-institute-of-research-and-rehabilitation-in-diabetes-endocrine-and-me","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}